

Center of Excellence Application - Test 2022

Application details

Center name

Scope

Submitted

Submitted by

Administrative contact

Company / Institution

Contact person

VAT Number

Invoice address

1. Structure (as in 2021)

Named GEP NET Specialists

Position

Responsible expert

1st GEP NET Specialist

2nd GEP NET Specialist

More GEP NET Specialists

Named PULM NET Specialists

Position

Responsible expert

1st PULM NET Specialist

2nd PULM NET Specialist

More PULM NET Specialists

1.1 Organizational Chart/ Management Structure

Position

Responsible expert

1.1.1 Head of the Center

1.1.2 Center coordination

1.1.3 Contact partner for all practitioners

1.1.4 Patient coordinator

1.1.5 Quality management coordinator

1.2 Main Partners / core partners

Position	Responsible expert
1.2.1 Gastroenterology	
1.2.2 Endocrinology	
1.2.3 Oncology	
1.2.4 Pathology	
1.2.5 Radiology	
1.2.6 Nuclear Medicine	
1.2.7 Visceral Surgery	
1.2.8 Endocrine Surgery	
1.2.9 Thoracic surgeon	
1.2.10 Pulmonologist	

1.3 Secondary Partners

Position	Responsible expert
1.3.1 Laboratory (accredited)	
1.3.2 Genetics (accredited laboratory)	
1.3.3 Cardiology	
1.3.4 Cardiac Surgery	
1.3.6 Transplant Surgery	
1.3.7 Radiotherapy	
1.3.8 Palliative care	
1.3.9 Pain Therapy	

1.4 Supportive Care Partners

Position	Responsible expert
1.4.1 Psychosocial support offers	
1.4.2 Nutrition expert	
1.4.3 Self-help-group	

1.5 Referring Partners / Affiliated Partners

Position	Responsible expert
1.5.1 University hospitals	
1.5.2 Non-university hospitals	
1.5.3 Physicians in private practice	

2. Interdisciplinary Cooperation and Communication Structure (as in 2021)

2.1. NET Tumor Board / Multidisciplinary Decision Making Team (MDT)

Position	Statement
2.1.1 Participants	
2.1.2.5 Frequency of Tumorboard meetings	

3. Specialist GEP NET Consultation (as in 2021)

3.1 Resources

Position	Statement
3.1.4 Number of NET specialists	Number:
SOP description	

4. Endocrinology (as in 2021)

4.1 Resources

Position	Statement
4.1.2 Number of endocrinologists	Number:
SOP description	

5. Gastroenterology (as in 2021)

5.1. Resources

Position	Statement
5.1.2 Number of gastroenterologists	Number:
5.1.5 Number of specialist endoscopists	Number:
5.1.6 Equipment	
SOP description	

6. Oncology (as in 2021)

6.1. Resources

Position	Statement
6.1.2 Number of oncologists	Number:

6.1. Resources

SOP description

7. Pathology (as in 2021)

7.1 Resources

Position	Statement
7.3.1 Number of pathologists	Number:
7.3.6 Number of pathologists in PULM	Number:
SOP description	

8. Radiology (as in 2021)

8.1 Resources

Position	Statement
8.1.2 Number of radiologists	Number:
SOP description	

9. Nuclear Medicine (as in 2021)

9.1 Resources

Position	Statement
9.1.2 Number of nuclear medicine experts	Number:
9.1.4 Equipment	
SOP description	

10. Surgery (as in 2021)

10.1. Resources

Position	Statement
10.1.2 Number of HBP surgeons	Number:
10.1.3 Number of thoracic surgeons	Number:
Hepato-bilio-pancreatic surgeon as liaison service?	Answer:
Thoracic surgeon as liaison service?	Answer:

11. Pulmonology (as in 2021)

11.1 Resources

Position	Statement
11.1.2 Number of pulmonologist	Number:
11.1.4 Number of specialist endoscopists	Number:
SOP description	

12. Scientific Activities (as in 2021)

12.1 GEP NET Research Group

Position	Statement
----------	-----------

Dedicated GEP NET research group	
----------------------------------	--

13. Patient Involvement (as in 2021)

13. Patient Involvement

Position	Statement
----------	-----------

13.1 How are your patients informed/involved?	
---	--

13.2 Patient feedback	
-----------------------	--

14. Follow-up and tumor documentation (as in 2021)

14. Follow-up and Tumor Documentation

Position	Statement
----------	-----------

Registry - how is your patient registry organized?	
--	--

Do you use electronic files?	
------------------------------	--

How is the follow-up organized?	
---------------------------------	--

15. Key Figures 2021

15.1 NET Patients

Position	Statement
----------	-----------

15.1.1 Number of new GEP NET patients	Number:
--	---------

15.1.2 New GEP NET patients treated in center	Number: Percentage:
---	------------------------

15.1.3 Number of current GEP NET patients	Number:
---	---------

15.1.4 Number of new PULM NET patients	Number:
---	---------

15.1.5 New PULM NET patients treated in center	Number: Percentage:
--	------------------------

15.1.6 Number of current PULM NET patients	Number:
--	---------

15.2 NET Tumor board / Multidisciplinary Decision Making Team (MDT)

Position	Statement
----------	-----------

15.2.1 GEP NET patients discussed in tumor board	Number of patients: Number of discussions:
--	---

15.2.2 Number of new GEP NET patients discussed in tumor board	Number:
---	---------

15.2.3 Number of second opinions	Number:
----------------------------------	---------

15.2.4 PULM NET patients discussed in tumor board	Number of patients: Number of discussions:
--	---

15.2 NET Tumor board / Multidisciplinary Decision Making Team (MDT)

15.2.5 Number of new PULM NET patients discussed in tumor board	Number:
15.2.6 Number of second opinions on PULM NET patients	Number:
15.2.7 Treatment decision making (outcome of the tumor board)	Surgery: Interventional radiology: Nuclear medicine: Medical therapies: Watch and wait: Others: Adherence to ENETS guidelines: Sample size:
15.2.8 Adherence to MDT decision making	Percentage: Sample size:

15.3 Specialist NET Consultation

Position	Statement
15.3.1 Waiting times	Waiting times consultation appointment (days): Period during which staging is concluded (days):

15.6 Oncology

Position	Statement
15.6.1 Number of NETS with systemic and targeted therapy (somatostatin therapy is excluded)	Interferon: Everolimus: Sunitinib: Other: Streptozocin/5-FU: Temozolomide/Capecitabine: Carbo- or Cisplatin/Etoposide: Other combinations:
15.6.2 Number of serious events	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.3 Number of deaths	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.4 Number of PULM NETS with systemic and targeted therapy (somatostatin therapy is excluded)	Interferon: Everolimus: Sunitinib: Other: Streptozocin/5-FU: Temozolomide/Capecitabine: Carbo- or Cisplatin/Etoposide: Other combinations:
15.6.5 Number of serious adverse events in PULM NET	Targeted therapy: Systemic therapy: Interferon therapy:
15.6.6 Number of deaths in PULM NET	Targeted therapy: Systemic therapy: Interferon therapy:

15.7 Pathology

Position	Statement
15.7.2 Reports on biopsies in GEP NET	Number:
15.7.3 Reports on surgical specimen in GEP NET	Number:

15.7 Pathology

15.7.4 Immunohistochemical examinations in GEP NET	Number:
15.7.5 Percentage of complete reports in GEP NET	Percentage:
15.7.7 Reports on biopsies in PULM NET	Number:
15.7.8 Reports on surgical specimen in PULM NET	Number:
15.7.9 Immunohistochemical examinations in PULM NET	Number:
15.7.10 Percentage of complete reports in PULM NET	Percentage:

15.8 Radiology

Position	Statement
15.8.2 TA(C)E	Number of TA(C)E in NET: Number of ablation in NET:
15.8.3 SIRT/intra-arterial PRRT with (radio) pharmaceuticals	SIRT in NET:
15.8.7 Morbidity in (combined) interventional radiology	Timeframe: Source: Number of serious adverse events:
15.8.8 Mortality in (combined) interventional radiology	Timeframe: Source: Number of deaths:

15.9 Nuclear Medicine

Position	Statement
15.9.1 Number of SSTR PET in NET	Number:
15.9.2 Number of FDG PET in NET	Number:
15.9.4 Therapeutic interventions in own center	All in own center: PRRT: MIBG: PRRT in combination with other treatments:
15.9.5 Therapeutic interventions in partner centers	All in partner center: PRRT: MIBG: PRRT in combination with other treatments:
15.9.6 Morbidity after therapeutic interventions	Timeframe: Source: Number of serious adverse events after PRRT: Number of serious adverse events after MIBG: Number of serious adverse events after PRRT in combination with other treatments:
15.9.7 Mortality after therapeutic interventions	Timeframe: Source: Number of deaths after PRRT: Number of deaths after MIBG: Number of deaths after PRRT in combination with other treatments:

15.10 Surgery

Position	Statement
15.10.1 Number of hepato-biliary surgeries	Partial hepatectomies: Radiofrequency assisted resection: Other:

15.10 Surgery

15.10.2 Number of hepato-biliary surgeries in GEP NET	Partial hepatectomies: Radiofrequency assisted resection: Other:
15.10.3 Number of pancreatic surgeries	Pancreaticoduodenectomy: Distal resection: Enucleation: Other:
15.10.4 Number of pancreatic surgeries in GEP NET	Pancreaticoduodenectomy: Distal resection: Enucleation: Other:
15.10.5 Number of bowel surgery in general	Stomach: Ileum: Colon: Rectum: Peritoneal resections: Other:
15.10.6 Number of bowel surgery in NET patients	Stomach: Ileum: Colon: Rectum: Peritoneal resections: Other:
15.10.7 Morbidity and mortality after hepato-biliary surgery in NET patients Index procedure : partial hepatectomy in NET	Timeframe: Source: Grade 3: Grade 4: Grade 5:
15.10.8 Morbidity and mortality after pancreatic surgery in NET patients Index procedure: pancreaticoduodenectomy in NET	Timeframe: Source: Grade 3: Grade 4: Grade 5:
15.10.9 Morbidity and mortality after bowel surgery in NET patients Index procedure: SI NET SURGERY	Timeframe: Source: Grade 3: Grade 4: Grade 5:
15.10.10 Number of thoracic surgeries in NET and non-NET patients	Anatomical lung resections: Atypical lung resections: Minimal invasive (video assisted) lung resections (VATS):
15.10.11 Number of thoracic surgeries in Pulm NET	Anatomical lung resections: Atypical lung resections: Minimal invasive (video assisted) lung resections (VATS):
15.10.12 Morbidity and mortality after thoracic surgery in NET patients Index procedure: Anatomical lung resections	Timeframe: Source: Grade 3: Grade 4: Grade 5:

15.12 Scientific activities

Position	Statement
15.12.1 Clinical trials	Prospective trials: NET patients in clinical trials: New NET patients in clinical trials:
15.12.2 Publications	Original articles: Other peer reviewed publications:

15.12 Scientific activities

15.12.3 Research projects	International studies: Retrospective analysis: Basic NET research: Research students (PhD): Research students (Lower grade): International exchange of experience:
---------------------------	---

15.13 Patient Questionnaire

Position	Statement
15.13.1 Percentage of patient questionnaire feedback	Percentage:

15.14 F / U data

Position	Statement
15.14.1 GEP NET patients in follow up	Number of GEP NET patients: Percentage of GEP NET patients:
15.14.2 GEP NET patients lost to follow up	Percentage of GEP NET patients lost:
15.14.3 PULM NET patients in follow up	Number of PULM NET patients: Percentage of PULM NET patients:
15.14.2 GEP NET patients lost to follow up	Percentage of PULM NET patients lost: